Related Experiment Video

Updated: Jun 11, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Do insulinotropic glucose-lowering drugs do more harm than good? The hypersecretion hypothesis revisited

I Rustenbeck1, S Baltrusch, M Tiedge

  • 1Institute of Pharmacology and Toxicology, University of Braunschweig, Mendelssohnstrasse 1, 38106 Braunschweig, Germany. i.rustenbeck@tu-bs.de

Diabetologia
|July 2, 2010
PubMed

Insights

Insulinotropic drugs for type 2 diabetes may harm beta cells by overstimulation. However, recent findings suggest these drugs might be beneficial by reducing beta cell stress if they avoid hypoglycemia.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Cell Biology

Background:

  • Type 2 diabetes pathogenesis involves beta cell dysfunction and death.
  • Glucolipotoxicity, oxidative stress, and endoplasmic reticulum stress contribute to beta cell damage.
  • Pharmacological stimulation of insulin secretion is a key treatment strategy.

Purpose of the Study:

  • To re-evaluate the long-term impact of insulinotropic drugs on beta cell mass and function.
  • To investigate the role of beta cell dysfunction in the early stages of type 2 diabetes.
  • To assess the potential benefits and risks of insulinotropic drugs in managing type 2 diabetes.

Main Methods:

  • Review of recent studies on beta cell signaling pathways in type 2 diabetes.
  • Analysis of the effects of glucolipotoxicity, oxidative stress, and ER stress on beta cells.
  • Evaluation of the evidence regarding the beta cell toxicity of insulinotropic drugs.

Main Results:

  • The traditional view of beta cell hypersecretion preceding deficit is challenged by new evidence.
  • Genetic risk factors primarily impact beta cell function, not just mass.
  • Evidence for beta cell toxicity from insulinotropic drugs remains inconclusive.
  • A secretion deficit may precede insulin resistance in type 2 diabetes pathogenesis.

Conclusions:

  • Insulinotropic glucose-lowering drugs may offer benefits by reducing beta cell stress from glucose overstimulation.
  • The risk of harm from these drugs is dependent on avoiding hypoglycemia and the specific drug's effect on beta cell mass.
  • A revised understanding of type 2 diabetes pathogenesis emphasizes the primary role of beta cell dysfunction.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...